One scan to catch two silent threats: MRI may spot bone and muscle loss in kidney patients
NCT ID NCT07645794
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explores whether a single MRI fat-fraction (MRI-FF) scan can accurately diagnose osteoporosis and sarcopenia (muscle loss) in people with chronic kidney disease (CKD). Researchers will compare MRI-FF results with standard DXA scans in 868 participants—half with CKD and half without. If proven reliable, MRI-FF could offer a faster, radiation-free way to detect these common complications early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MRI fat-fraction (MRI-FF) scan
What this could lead to
If successful, this could provide a single, non-invasive scan to detect both osteoporosis and sarcopenia early in CKD patients, improving diagnosis without radiation.
What could go wrong
This is an observational study, not a treatment trial. The MRI-FF method may not prove accurate enough to replace current standards like DXA, and results may not apply to all CKD stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••